- Coluracetam
-
- $2.00/ kg
-
2024-06-09
- CAS:135463-81-9
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
- COLURACETAM
-
- $108.00 / 50Grams
-
2024-06-07
- CAS:135463-81-9
- Min. Order: 50Grams
- Purity: 99.99%
- Supply Ability: 100Tons
- COLURACETAM
-
- $0.00 / 1kg
-
2024-06-04
- CAS:135463-81-9
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 2000
|
| | Coluracetam Basic information |
| Product Name: | Coluracetam | | Synonyms: | COLURACETAM;N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxopyrrolidin-1-yl)acetamide;1-Pyrrolidineacetamide,2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethylfuro[2,3-b]quinolin-4-yl)-;Coluracetam, MKC-231;1-[N-(2,3-DiMethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)carbaMoylMethyl]pyrrolidin-2-one;BCI-540;Coluracetam, >=99%;2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethyl-furo[2,3-b]quinolin-4-yl)-1-pyrrolidineacetamide | | CAS: | 135463-81-9 | | MF: | C19H23N3O3 | | MW: | 341.4 | | EINECS: | 1308068-626-2 | | Product Categories: | Brain health drug;Nootropic;pharmaceutical intermediate or medicine grade;pharmaceutical | | Mol File: | 135463-81-9.mol |  |
| | Coluracetam Chemical Properties |
| Boiling point | 634.1±55.0 °C(Predicted) | | density | 1.291±0.06 g/cm3(Predicted) | | storage temp. | Sealed in dry,Room Temperature | | solubility | DMF: 1 mg/ml; DMSO: 2 mg/ml; Ethanol: 2 mg/ml; PBS (pH 7.2): insol | | form | A crystalline solid | | pka | 12.01±0.20(Predicted) | | InChI | InChI=1S/C19H23N3O3/c1-11-12(2)25-19-17(11)18(13-6-3-4-7-14(13)20-19)21-15(23)10-22-9-5-8-16(22)24/h3-10H2,1-2H3,(H,20,21,23) | | InChIKey | PSPGQHXMUKWNDI-UHFFFAOYSA-N | | SMILES | N1(CC(NC2C3=C(N=C4OC(C)=C(C)C4=2)CCCC3)=O)CCCC1=O |
| | Coluracetam Usage And Synthesis |
| Uses | Copiracetam can be used as a nootropic drug to treat memory and intellectual impairments caused by senile dementia, mild to moderate vascular dementia, trauma and other diseases, and to promote children's intellectual development; it also has antidepressant effects. | | Pharmacology | Copiracetam has the ability to improve cognition by participating in the HACU process, increasing the rate-limiting step of synaptic intake of choline to synthesize the neurotransmitter acetylcholine, and increasing the activity of cholinergic neurons. | | in vitro |
Coluracetam (10(-10)-10(-6) moll), also known as MKC-231, significantly increased high affinity choline uptake (HACU) when it was incubated with the hippocampal synaptosomes of ethylcholine mustard aziridinium ion (AF64A) treated rats, but not of normal rats. MKC-231 did not affect the AChE activity, [3H]- quinuclidinyl benzilate binding, and [3H]-pirenzepine binding.
| | in vivo | Oral administration of MKC-231 (Coluracetam; 1-10 mg/kg) significantly improved the learning deficits in the Morris' water maze of AF64A-treated rats, but it did not produce any significant side effects, like tremor, salivation or hypothermia, which were observed in rats treated with high doses of tacrine [1]. In acute behavioral experiments, MKC-231 and THA had no significant effect on AF64A-induced memory deficits at any doses tested (0.3, 1.0 and 3.0 mg/kg), whereas Dup 996, at a dose of 1.0 mg/kg, significantly improved memory deficits. In chronic experiments, MKC-231 improved memory deficit at all doses tested (0.3, 1.0, or 3.0 mg/kg p.o., once daily for 11 days) and Dup 996 did so only at a dose of 3.0 mg/kg, whereas THA did not improve memory deficit at any doses tested.
|
| | Coluracetam Preparation Products And Raw materials |
|